Yang B, Huang S, Li S, Feng Z, Zhao G, Ma Q
Front Vet Sci. 2022; 9:895831.
PMID: 35685343
PMC: 9171047.
DOI: 10.3389/fvets.2022.895831.
Zhou W, Anakk S
Mol Cell Endocrinol. 2022; 549:111616.
PMID: 35304191
PMC: 9245558.
DOI: 10.1016/j.mce.2022.111616.
Ma Y, Harris J, Li P, Cao H
Mol Cell Endocrinol. 2021; 525:111191.
PMID: 33539963
PMC: 8437140.
DOI: 10.1016/j.mce.2021.111191.
Porez G, Prawitt J, Gross B, Staels B
J Lipid Res. 2012; 53(9):1723-37.
PMID: 22550135
PMC: 3413216.
DOI: 10.1194/jlr.R024794.
Haeusler R, Pratt-Hyatt M, Welch C, Klaassen C, Accili D
Cell Metab. 2011; 15(1):65-74.
PMID: 22197325
PMC: 3253887.
DOI: 10.1016/j.cmet.2011.11.010.
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.
Mencarelli A, Cipriani S, Renga B, Francisci D, Palladino G, Distrutti E
PLoS One. 2010; 5(10):e13238.
PMID: 20949026
PMC: 2951893.
DOI: 10.1371/journal.pone.0013238.
FXR an emerging therapeutic target for the treatment of atherosclerosis.
Mencarelli A, Fiorucci S
J Cell Mol Med. 2010; 14(1-2):79-92.
PMID: 20041971
PMC: 3837604.
DOI: 10.1111/j.1582-4934.2009.00997.x.
Decreased expression of cholesterol 7alpha-hydroxylase and altered bile acid metabolism in Apobec-1-/- mice lead to increased gallstone susceptibility.
Xie Y, Blanc V, Kerr T, Kennedy S, Luo J, Newberry E
J Biol Chem. 2009; 284(25):16860-16871.
PMID: 19386592
PMC: 2719322.
DOI: 10.1074/jbc.M109.010173.
Physical activity as a determinant of fecal bile acid levels.
Wertheim B, Martinez M, Ashbeck E, Roe D, Jacobs E, Alberts D
Cancer Epidemiol Biomarkers Prev. 2009; 18(5):1591-8.
PMID: 19383885
PMC: 2743306.
DOI: 10.1158/1055-9965.EPI-08-1187.
Endocrine functions of bile acids.
Houten S, Watanabe M, Auwerx J
EMBO J. 2006; 25(7):1419-25.
PMID: 16541101
PMC: 1440314.
DOI: 10.1038/sj.emboj.7601049.
Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.
Iser J, Sali A
Drugs. 1981; 21(2):90-119.
PMID: 7009140
DOI: 10.2165/00003495-198121020-00002.
[Relation between serum lipoprotein metabolism and biliary lipid metabolism].
Leiss O, von Bergmann K
Klin Wochenschr. 1983; 61(12):579-92.
PMID: 6876687
DOI: 10.1007/BF01487336.
Dissolving gall stones.
Bateson M
Br Med J (Clin Res Ed). 1982; 284(6308):1-3.
PMID: 6797617
PMC: 1495392.
DOI: 10.1136/bmj.284.6308.1.
Regulation and interaction of cholesterol, bile salt and lipoprotein synthesis in liver.
Barth C
Klin Wochenschr. 1983; 61(23):1163-70.
PMID: 6361370
DOI: 10.1007/BF01537427.
Does chenodesoxycholic acid have a lipid lowering effect in primary hyperlipoproteinemia?.
Schlierf G, Stiehl A, Heuck C, Lang P, Oster P, Schellenberg B
Eur J Clin Pharmacol. 1976; 10(2):147-9.
PMID: 964291
DOI: 10.1007/BF00609474.
The effect of wheat bran upon bile salt metabolism and upon the lipid composition of bile in gallstone patients.
Pomare E, Heaton K, ESPINER H
Am J Dig Dis. 1976; 21(7):521-6.
PMID: 941893
DOI: 10.1007/BF01464757.
Editorial: Progress in dissolving gallstones.
Br Med J. 1975; 1(5960):699-700.
PMID: 804950
PMC: 1672716.
DOI: 10.1136/bmj.1.5960.699.
Hypolipaemic drugs and coronary heart disease.
Howard A
J Clin Pathol Suppl (R Coll Pathol). 1975; 9:106-14.
PMID: 783209
PMC: 1347190.
Treatment with bile acids.
Br Med J. 1978; 2(6133):309.
PMID: 687894
PMC: 1606413.
Clofibrate therapy and gallstone induction.
Bateson M, Maclean D, Ross P, Bouchier I
Am J Dig Dis. 1978; 23(7):623-8.
PMID: 685927
DOI: 10.1007/BF01072597.
